Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Influenza vaccine quadrivalent - Seqirus

Drug Profile

Influenza vaccine quadrivalent - Seqirus

Alternative Names: Afluria Quad; AFLURIA QUADRIVALENT; aQIV; CSL QIV; Influenza vaccine quadrivalent - bioCSL; Quadrivalent influenza vaccine - (CSL-QIV); Quadrivalent influenza vaccine - bioCSL; Quadrivalent influenza vaccine - Seqirus; Seqirus QIV; Split virion inactivated quadrivalent influenza vaccine - bioCSL

Latest Information Update: 10 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator bioCSL
  • Developer Seqirus
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 23 Oct 2023 Seqirus initiates enrolment in a phase III trial for Influenza virus infections (Prevention) in Belgium (NCT06087640)
  • 07 Dec 2022 No development reported - Phase-III for Influenza virus infections (In children, In infants, Prevention) in Canada (IM) (NCT01964989)
  • 07 Dec 2022 No development reported - Phase-III for Influenza virus infections (In children, In infants, Prevention) in Finland (IM) (NCT01964989)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top